• Introductions: HMTRC Director, Dr. Dan Vigneron PhD & Chair of Radiology & Biomedical Imaging, Dr. Christopher Hess MD, PhD

• Center Updates on Hyperpolarized C-13 MRI Technology Development: HMTRC Director, Dr. Dan Vigneron PhD

• Hyperpolarized C-13 MRI Clinical Translation Update: Dr. Jane Wang MD, HP Medical Director

• Technology Development for Polarizer and Detector Instrumentation: Dr. Jeremy Gordon PhD & Duy Dang PharmD

• Development of Novel Hyperpolarized (HP) MR Molecular Imaging Probes Tested in Realistic Preclinical Models and Correlative Science Studies: Drs. John Kurhanewicz PhD & Renuka Sriram PhD

• Acquisition and Analysis Methods for Hyperpolarized MR Data: Drs. Duan Xu PhD & Peder Larson PhD 

• Dr. Jae Mo Park PhD, University of Texas Southwestern: Imaging Mitochondrial Metabolism using Hyperpolarized C-13 Pyruvate
• Dr. Kayvan Keshari PhD, Memorial Sloan Kettering Cancer Center, NY: Can we make metabolism great again?
• ​Dr. Chris Laustsen PhD, Aarhus University: Is there a place for cardiac hyperpolarized [1-¹³C]pyruvate in the clinical toolbox?
• Dr. Chuck Cunningham PhD, University of Toronto: Hyperpolarized C-13 MRI of the Human Brain
• Dr. Gigin Lin MD PhD, Chang Gung Memorial Hospital, Taiwan: Hyperpolarized C-13 MRI Evaluate Immune Metabolism
• Dr. Jan Ardenkjaer-Larsen PhD, Technical University of Denmark: Hyperpolarized MR
• Dr. Robert Bok MD PhD, UCSF: Update of Hyperpolarized C-13 MRI for Active Surveillance in Prostate Cancer Subjects

• Dr. James Kempf PhD, Bruker Scientist: Versatile, High-throughput d-DNP with Bruker
• Dr. Titus Lanz PhD, RAPID Biomedical GmbH: A Dual Tuned C-13/H-1 Array for Torso Application
• Dr. Sella Brosh MD, NVision Imaging Technologies: NVISION Hyperpolarized MRI made simple

• Keynote Lecture by Dr. Donna Peehl PhD, UC San Francisco: Preclinical HP C-13 MRI: Looking Back and Looking Forward

• Keynote Lecture by Dr. Ferdia Gallagher MD PhD, University of Cambridge: The Potential for Metabolic Imaging

• Dr. Stephen Lai MD PhD, UT MD Anderson Cancer Center: Developing a Quantifiable Imaging-Based Biomarker
• Dr. Ivan De Kouchkovsky MD – Rahul Aggarwal MD, UCSF: Emerging Clinical Applications of Hyperpolarized C-13 MRI in Prostate Cancer

• Dr. Myriam Chaumeil PhD, UCSF: Recent advances in preclinical HP C-13 metabolic neuroimaging
• Dr. Vlad Zaha MD PhD, University of Texas Southwestern: Lessons from Using Hyperpolarized C-13 labeled Substrates in Cardio-Oncology
• Dr. Yaewon Kim PhD, UCSF: Clinical HP C-13 MR Molecular Imaging: Probes beyond [1-¹³C]Pyruvate
• Dr. Adam Retter MD PhD Candidate, University College London: C-13 Pyruvate Hyperpolarised MR in patients with prostate cancer on active surveillance
• Dr. Yan Li MD PhD, UCSF: Imaging Tumor Metabolism for Improved Management of Patients with Glioma
• Dr. Dan Crooks MS PhD, NIH/NCI: Metabolic and Mitochondrial Heterogeneity in Fumarate Hydratase-Deficient Renal Tumors

• Dr. Matthew Merritt PhD, University of Florida: Investigating Pancreas Metabolism with Hyperpolarized [1-¹³C]Pyruvate
• Dr. Pavithra Viswanath PhD, UCSF: Probing the pentose phosphate pathway in brain tumors using hyperpolarized C-13 imaging
• Alba Herrero Gomez, Institute for BioEngineering Catalonia, Barcelona: Hyperpolarization-enhanced NMR and MRI methods for tissue engineering applications
• Dr. Xiaoxi Liu PhD, UCSF: Metabolite-Specific 3D bSSFP Sequences for Hyperpolarized C-13 MRI
• Dr. Jan-Bernd Höevener PhD, University of Kiel: SpinAlinger dDNP 2.5 years and 370 dissolutions in 
• Dr. Hsin-Yu Chen PhD, UCSF: Hyperpolarized ¹³C Pyruvate MR-Assisted Longitudinal Risk Stratification in Prostate Cancer Patient – From Surveillance to Surgery